Positive results presented by Celldex Therapeutics on Barzolvolimab studies showing improved quality of life

From GlobeNewswire: 2025-03-01 12:45:00

Celldex Therapeutics, Inc. shared positive data on Barzolvolimab studies, showing improved quality of life in patients with chronic urticaria. 82% of CSU patients and 60% of CIndU patients reported no impact on quality of life at Week 52. The Phase 2 studies demonstrated rapid and sustained improvement in urticaria control using UCT and DLQI measurements. The data was presented at the AAAAI Annual Meeting. Patients with CSU and CIndU showed meaningful improvements, highlighting the potential for Barzolvolimab to change the treatment paradigm. Global Phase 3 studies are enrolling for CSU and CIndU with plans to advance into Phase 3 development in 2025.



Read more at GlobeNewswire: Celldex Therapeutics Presents Positive Results from